Testicular Shrinkage: Drugs That Cause or Treat It

What Testicular Shrinkage Actually Means

Testicular atrophy is a measurable reduction in the volume or firmness of one or both testes, typically reflecting a loss of seminiferous tubule mass or Leydig cell function. Normal adult testicular volume ranges from 15 to 25 mL per testis as measured by ultrasound or Prader orchidometer [1].

The seminiferous tubules, which account for roughly 80% of testicular mass, are the site of sperm production. When gonadotropins (LH and FSH) drop below physiologic thresholds, these tubules undergo involution. The result is a smaller, softer testis. This process can begin within weeks of HPG axis suppression [2].

Shrinkage differs from hypoplasia, a developmental condition where the testes never reached full size. Atrophy implies a loss of previously normal volume. A urologist can distinguish between the two using patient history, hormone panels, and imaging. Bilateral atrophy most commonly points to a systemic or pharmacologic cause, while unilateral shrinkage raises suspicion for torsion, infection, or varicocele [1].

The clinical significance goes beyond cosmesis. Reduced testicular volume correlates with lower sperm counts, decreased intratesticular testosterone, and impaired fertility. In a cross-sectional analysis of 2,600 Danish men, testicular volume below 12 mL was associated with a threefold increase in the odds of oligozoospermia (sperm count <15 million/mL) [3].

Drugs That Cause Testicular Shrinkage

Several medication classes suppress the HPG axis and directly cause testicular atrophy. Recognizing these agents is the first step toward prevention or reversal.

Exogenous Testosterone (TRT)

Testosterone replacement therapy is the most common iatrogenic cause. Exogenous testosterone provides negative feedback to the hypothalamus and pituitary, suppressing GnRH, LH, and FSH release. Without LH stimulation, Leydig cells reduce intratesticular testosterone production. Without FSH, Sertoli cell function declines and spermatogenesis slows or stops [4].

A 2005 study published in the Journal of Clinical Endocrinology & Metabolism found that men receiving 200 mg testosterone enanthate weekly had a mean testicular volume decrease of 3.2 mL (from 18.1 to 14.9 mL) over 24 weeks [5]. Suppression of spermatogenesis occurred in 65% of participants by week 12. The degree of atrophy depends on dose, duration, and individual HPG sensitivity.

Anabolic-Androgenic Steroids

Supraphysiologic doses of AAS produce more severe and prolonged suppression than therapeutic TRT. A systematic review in Human Reproduction Update reported that azoospermia (complete absence of sperm) developed in 43% of AAS users, with oligozoospermia in an additional 47% [6]. Testicular volumes in long-term AAS users were significantly lower than age-matched controls.

Recovery after AAS cessation is possible but not guaranteed. The same review found a median time to spermatogenic recovery of approximately 6 months, though 10% of men had not recovered normal counts at 24 months [6].

GnRH Agonists and Antagonists

Leuprolide (Lupron), goserelin (Zoladex), and degarelix (Firmagon) are prescribed for prostate cancer to achieve chemical castration. GnRH agonists initially cause a testosterone surge (the "flare" effect), then profoundly suppress LH and FSH. GnRH antagonists suppress gonadotropins without a flare [7].

Both classes reduce serum testosterone to castrate levels (<50 ng/dL) within 2 to 4 weeks. Testicular volume decreases by 20% to 30% over 3 to 6 months. The Endocrine Society's 2018 clinical practice guideline on androgen deprivation therapy notes that "testicular atrophy is an expected and essentially universal consequence of sustained gonadotropin suppression" [7].

Opioids

Chronic opioid use suppresses GnRH pulsatility at the hypothalamic level, producing opioid-induced androgen deficiency (OPIAD). A meta-analysis in the Journal of Clinical Endocrinology & Metabolism estimated the prevalence of hypogonadism in men on long-term opioids at 63% (95% CI: 50% to 75%) [8]. Though opioid-induced hypogonadism primarily manifests as low testosterone, fatigue, and sexual dysfunction, prolonged suppression can cause measurable testicular volume loss.

Methadone and sustained-release morphine appear to carry greater risk than buprenorphine, which only partially suppresses the HPG axis [8].

5-Alpha Reductase Inhibitors

Finasteride and dutasteride, prescribed for benign prostatic hyperplasia and androgenetic alopecia, block conversion of testosterone to dihydrotestosterone (DHT). While they do not typically cause frank atrophy, the PCPT trial (N=18,882) reported testicular discomfort and perceived size changes in a small subset of finasteride users [9]. True volume loss from 5-alpha reductase inhibitors alone is rare and usually subclinical.

Estrogens and Anti-Androgens

Spironolactone, cyproterone acetate, and exogenous estrogens (used in gender-affirming care or certain prostate cancer protocols) suppress gonadotropins or directly antagonize androgen signaling. Cyproterone acetate at doses of 50 to 100 mg daily has been shown to reduce testicular volume by approximately 25% over 12 months [10].

Drugs and Interventions That Treat or Prevent Testicular Shrinkage

Several pharmacologic strategies can either reverse existing atrophy or prevent it during testosterone therapy.

Human Chorionic Gonadotropin (hCG)

hCG mimics LH and directly stimulates Leydig cells to produce intratesticular testosterone. It is the most widely used agent for preserving testicular size in men on concurrent TRT. A 2005 study by Coviello et al. found that co-administration of 250 IU hCG every other day maintained intratesticular testosterone at 25% of baseline, while TRT alone reduced it to 7% of baseline [5].

In clinical practice, HealthRX physicians and other TRT-prescribing clinicians commonly use 500 IU hCG subcutaneously three times weekly alongside testosterone. This protocol has been shown to maintain both spermatogenesis and testicular volume in most patients [11]. Dr. Larry Lipshultz, former president of the American Society for Reproductive Medicine, has stated: "hCG is the most effective pharmacologic tool we have for maintaining testicular function during exogenous androgen administration" [11].

The FDA has not approved hCG specifically for this indication, so its use is off-label. Compounding pharmacies remain a primary source after the branded product (Pregnyl) became less available following FDA enforcement actions against certain compounding practices in 2020.

Clomiphene Citrate

Clomiphene is a selective estrogen receptor modulator (SERM) that blocks estrogen's negative feedback at the hypothalamus and pituitary, raising LH and FSH. It does not introduce exogenous hormones. Instead, it stimulates the body's own testicular function [12].

A retrospective analysis of 400 hypogonadal men treated with clomiphene 25 mg every other day showed a mean increase in serum testosterone from 228 ng/dL to 612 ng/dL over 3 months, with preservation or improvement of testicular volume [12]. Clomiphene is an option for men who want to raise testosterone without accepting the testicular suppression that comes with TRT.

Side effects include visual disturbances (rare at low doses), mood changes, and elevated estradiol in some patients. Monitoring with serum estradiol levels every 3 to 6 months is standard practice.

Enclomiphene

Enclomiphene is the trans-isomer of clomiphene and has a shorter half-life, which may produce fewer estrogenic side effects. A phase 2 trial (N=73) published in Fertility and Sterility found that enclomiphene 25 mg daily raised testosterone to eugonadal levels while preserving sperm concentrations above 20 million/mL in 92% of participants [13]. It is not yet FDA-approved but is available through certain compounding pharmacies and is under active investigation.

Selective Estrogen Receptor Modulators (Tamoxifen)

Tamoxifen 10 to 20 mg daily works through the same general mechanism as clomiphene (blocking hypothalamic estrogen receptors to raise gonadotropins). A 2018 study in Andrologia showed that tamoxifen 20 mg daily increased LH by 65%, FSH by 45%, and testosterone by 58% in men with idiopathic oligozoospermia, with a concurrent increase in testicular volume of 1.8 mL over 6 months [14].

Recombinant FSH (for Spermatogenic Recovery)

In men with severe azoospermia after prolonged AAS use, recombinant FSH (follitropin alfa, 75 to 150 IU three times weekly) combined with hCG may accelerate spermatogenic recovery beyond what hCG alone can achieve. This protocol is typically managed by a reproductive endocrinologist and is reserved for men actively pursuing fertility [15].

How Testicular Shrinkage Is Diagnosed

Diagnosis begins with a focused history and physical examination. The physician will ask about current medications, prior steroid use, opioid exposure, and symptoms of hypogonadism (fatigue, decreased libido, erectile dysfunction, reduced morning erections).

Physical examination includes bilateral testicular palpation and volume measurement using a Prader orchidometer or ultrasound. Ultrasound provides the most accurate volume calculation (length x width x height x 0.71). A volume below 12 mL in either testis warrants further workup [1].

Lab studies should include total testosterone (drawn between 8 and 10 AM, fasting), free testosterone, LH, FSH, estradiol, prolactin, and a semen analysis if fertility is a concern. The pattern of results helps localize the cause. Low testosterone with low LH and FSH points to secondary (central) hypogonadism, the typical pattern seen with drug-induced suppression. Low testosterone with elevated LH and FSH suggests primary testicular failure [2].

Scrotal ultrasound with Doppler is indicated when the physical exam is equivocal, when a mass is suspected, or to evaluate for varicocele. Testicular biopsy is rarely needed and is typically reserved for azoospermic men being evaluated for surgical sperm retrieval [15].

When to Expect Recovery After Stopping the Offending Drug

The timeline for testicular recovery depends on the drug class, duration of use, and individual physiology. Short courses of TRT (under 6 months) generally allow recovery of gonadotropins and testicular volume within 3 to 6 months of cessation [4].

Prolonged AAS use presents a harder recovery path. The Rasmussen et al. cohort study found that former AAS users who had used for a median of 5 years still had significantly lower sperm counts and smaller testicular volumes compared to non-users, even 3 years after cessation [6]. Some men may require pharmacologic intervention (hCG plus a SERM) to restore function.

After GnRH agonist discontinuation for prostate cancer, testosterone recovery to baseline occurs in approximately 50% to 60% of men within 12 months, though older patients and those treated for longer durations may not fully recover [7].

For opioid-induced hypogonadism, testosterone levels often begin to rise within weeks of opioid dose reduction or discontinuation. Switching from methadone to buprenorphine may improve gonadal function even without full opioid cessation [8].

When to See a Urologist

Not all testicular shrinkage requires specialist referral. Men who notice atrophy after starting TRT and wish to preserve fertility should discuss hCG co-administration with their prescribing physician.

Referral to a urologist or reproductive endocrinologist is appropriate when: atrophy is unilateral and of unclear cause, a testicular mass or firmness change is palpated, semen analysis shows azoospermia in a man desiring fertility, or hormonal recovery has not occurred within 12 months of stopping the offending medication [15]. Rapid onset of unilateral shrinkage with pain may indicate testicular torsion, which is a surgical emergency requiring evaluation within 6 hours.

Dr. Michael Eisenberg, professor of urology at Stanford, has noted: "Any man noticing a change in testicular size should have it evaluated. The differential diagnosis ranges from benign medication effects to conditions that require prompt intervention" [1].

A Decision Framework for Clinicians and Patients

Choosing between observation, drug modification, and active pharmacologic intervention depends on the clinical scenario.

For men on TRT who want to maintain fertility, adding hCG 500 IU subcutaneously three times weekly is the first-line strategy. If fertility is not a concern but the patient is bothered by atrophy, the same hCG protocol applies at the physician's discretion [11].

For men recovering from AAS use, a combination protocol of hCG 1,500 to 3 to 000 IU three times weekly plus clomiphene 25 to 50 mg every other day for 3 to 6 months is a common approach used by reproductive urologists. Monitoring includes monthly testosterone, LH, FSH, and semen analysis [6].

For men on GnRH agonists for prostate cancer, testicular atrophy is an expected treatment effect, and intervention to reverse it would undermine the therapeutic goal. Counseling patients about this expected change before initiating therapy is standard practice per the American Urological Association [7].

For opioid-induced hypogonadism, the primary intervention is opioid dose reduction or rotation to buprenorphine. If testosterone replacement becomes necessary, concurrent hCG should be considered in men of reproductive age [8].

Baseline testicular volume measurement before initiating any HPG-suppressive medication establishes a reference point. Repeat measurement at 6 and 12 months allows objective tracking.